Benefits of Early Aspirin Discontinuation in Low-Risk Heart Attack Patients
Research shows that early discontinuation of aspirin after MI in low-risk patients can reduce bleeding risk without increasing adverse events, thanks to advancements in revascularization techniques.
Recent research suggests that for low-risk patients who experience a myocardial infarction (heart attack) and undergo early complete revascularization, stopping aspirin therapy after one month may be safe and beneficial. A large European trial involving nearly 2,000 participants demonstrated that switching from dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy after one month did not increase the risk of adverse cardiovascular events such as death, heart attacks, or stroke. Instead, this approach significantly reduced bleeding complications, a common concern with prolonged aspirin use.
The study, presented at ESC Congress 2025 and published in the New England Journal of Medicine, involved patients who received modern drug-eluting stents and achieved complete revascularization within a week of their MI. These participants continued with DAPT—aspirin plus a P2Y12 inhibitor—for one month, after which they were randomized to either remain on DAPT or switch to P2Y12 inhibitor monotherapy for the following 11 months.
Findings showed comparable rates of major cardiovascular events between both groups, with the monotherapy group experiencing fewer significant bleedings. The overall composite outcome—covering death, MI, stent thrombosis, stroke, and major bleeding—was lower in patients who discontinued aspirin early. Lead investigator Professor Giuseppe Tarantini explained that in carefully selected low-risk patients, early de-escalation could balance protection from ischemic events while minimizing bleeding risks, thanks to advancements in stent technology and medical care.
These results challenge traditional guidelines, which recommend 12 months of DAPT after MI, suggesting that tailored, shorter-duration therapy may be appropriate for certain low-risk groups. The study highlights the importance of modern revascularization techniques and personalized therapy in optimizing patient outcomes.
Source: https://medicalxpress.com/news/2025-09-early-aspirin-discontinuation-linked-benefits.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Gut Microbes and Acetate Synergy Promote Fat Loss in Mice Without Muscle Wastage
A recent study reveals that enhancing acetate levels in the gut, alongside specific Bacteroides bacteria, can reduce fat in mice without muscle loss, offering promising insights for obesity treatment through microbiome modulation.
Exploring the Role of Artificial Intelligence in Modern Rheumatology
Discover how artificial intelligence is revolutionizing rheumatology through improved diagnosis, disease monitoring, and patient communication with the latest research from EULAR 2025.
Rise in Alcohol-Related Liver Disease: A Sharp Increase Over Two Decades
A new study reveals that alcohol-related liver disease has more than doubled over the past 20 years in the United States, highlighting demographic shifts and the need for targeted interventions. Learn how changing patterns of alcohol use increase liver health risks.